Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities

Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.

Original reporting
Published Nov 16, 2026, 2:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities — source image
Decision brief

The 30-second read

$UNCYBullishMed
01

Why it matters

The FDA’s acceptance and the March 25, 2027 PDUFA target date create a clearer regulatory timeline, while the cash runway extension beyond 2027 reduces financing risk. However, vendor-related manufacturing readiness and potential pre-approval inspection remain key execution risks.

02

Market read

Traders get a concrete FDA milestone (acceptance plus PDUFA date) and updated liquidity/runway, which can shift probability-weighted valuation for a small-cap biotech.

03

What to watch

CMS TDAPA eligibility is contingent on FDA approval and CMS confirmation, so reimbursement upside may be delayed or reduced if eligibility criteria are not met.

Relevance 7/10Novelty 7/10Timing: PDUFA catalyst set for March 25, 2027, with Q3 cash/runway disclosed now.

Background

Unicycive resubmitted its oxylanthanum carbonate (OLC) NDA after a June 2026 Complete Response Letter citing deficiencies at the original drug product vendor, without new clinical efficacy or safety concerns.

Company-level read

Ticker impact

$UNCYBullishMedium confidence
Context

Unicycive Therapeutics reports Q3 2026 results and says the FDA accepted its resubmitted OLC NDA with a March 25, 2027 PDUFA action date.

Expected impact

Likely upward bias as traders price improved regulatory path and a clear catalyst date, offset by ongoing vendor-inspection uncertainty.

Evidence & confidence

The article provides a fresh regulatory milestone (FDA acceptance plus PDUFA target date) and cash runway details, both of which can affect valuation and probability-weighted outcomes.

Market effects

Reinforces that dialysis-phosphate binder reimbursement and TDAPA eligibility can materially affect biotech commercial economics.

None specific beyond US FDA/CMS policy relevance.

Limited, primarily US regulatory and reimbursement-driven.

Counterpoint

The FDA acceptance does not guarantee approval, and the article flags uncertainty around whether a pre-approval inspection will occur.

Key entities

  • Unicycive Therapeutics

    Reports Q3 2026 financials and provides an FDA timeline for its resubmitted OLC NDA.

  • Oxylanthanum carbonate (OLC)

    Dialysis phosphate binder whose NDA resubmission was accepted by the FDA with a March 25, 2027 PDUFA target date.

  • FDA

    Accepted the OLC NDA resubmission and set a PDUFA target action date.

  • CMS

    Finalized dialysis base rate addition effective January 1, 2027 and a hyperphosphatemia clinical quality measure beginning payment year 2029.

Related articles

$UNCYMed

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update - New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.

$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.